Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hangzhou Diagens Biotechnology Co., Ltd.
杭州德適生物科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2526)

VOLUNTARY ANNOUNCEMENT
GLOBAL LAUNCH OF THE UPGRADED iMedLoop™ PLATFORM AND OPENING OF API SUBSCRIPTION

This announcement is made by Hangzhou Diagens Biotechnology Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments.

The board of directors of the Company (the "**Board**") is pleased to announce that the medical imaging model development, research and analysis platform of the Group, namely, the upgraded iMedLoop™ platform (the "**Platform**"), was officially launched at 9:00 a.m. Eastern Standard Time on 18 November 2026 (www.imedloop.com). The Group also opened API subscriptions worldwide at the same time.

The main feature of this upgrade is the integration of the Group's sixth-generation medical imaging foundation model, iMedImage® 6.0 (iMed-6.0), and the extension of image analysis capabilities towards the general users. Users may choose to use the specialized models provided by the Platform, or utilize the Platform to train, evaluate, and deploy customized specialized models without programming. Professional users can utilize the Platform's tools to organize and analyze imaging data, and can also access the model's capabilities within their own research systems through API subscriptions.

Users can independently choose the specialized models provided by the Platform or models developed by themselves, upload various types of medical imaging or examination reports, and obtain interpretations presented in plain language, serving as a reference for understanding imaging findings and discussing examination results with doctors.

The Group has accumulated a medical imaging dataset of over 1.1 billion images, covering 19 imaging modalities. iMed-6.0 was trained on this extensive dataset and has capabilities including three-dimensional anatomical localization lesion measurement, and dynamic image analysis.

The Board considers that the global launch of the upgraded Platform and the concurrent opening of API subscriptions represent a significant step for the Group in upgrading its business model and expanding into the international market. Based on the accumulated research and development and institutional service experience, the Group provides services through the Platform to overseas medical institutions, scientific research teams, independent researchers and developers. Online platform services and API subscriptions complement the existing institutional model licensing and localized delivery, which facilitates the Group in expanding its customer base and sources of revenue.

The Board believes that extending intelligent image interpretation services to a wider range of users will help people worldwide better understand their examination results and manage their own health more proactively. The Group expects that, through iMedLoop™, medical artificial intelligence will benefit more people worldwide, ushering in a new era of intelligent health management.

Personal image interpretation is provided solely to help users understand health information and for general science education; clinical diagnosis should be made by qualified medical professionals. Relevant model functions that require regulatory approval but have not yet been approved are solely for research validation and exploratory teaching purposes. Uncertainties remain regarding the availability of Platform services and the effectiveness of their commercialization.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Hangzhou Diagens Biotechnology Co., Ltd.
Song Ning
Chairman of the Board, Executive Director and General Manager

Hangzhou, PRC, November 19, 2026

As of the date of this announcement, the Board comprises: (i) Dr. Song Ning and Mr. Weng Chih-Hsin (alias Robin Weng) as executive Directors; (ii) Dr. Xu Chen, Dr. Wu Lingqian and Mr. Yang Zehao as non-executive Directors; and (iii) Mr. Cha Yang (alias Stanley Cha), Ms. Zhang Jing and Mr. Wang Kaifeng as independent non-executive Directors.